Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 4 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 9:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 3100 MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers. Schwartzberg L Spigel D Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2584 Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial. Spira A Naqash A Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 3084 Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/ refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). Khawaja MR Naqash A Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2524 Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma. Ulahannan S Ulahannan S Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 3029 Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types. Rugo H O'Shaughnessy J Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2617 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival. Zakharia Y Jotte R, Gillespie-Twardy A, Watson G, Ward P, Cowey CL Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2538 A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability- low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Christenson E Manda S, Hutson T, Spira A Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 1594 Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). Lee YC Monk B Care Delivery/Models of Care 9:00am - 12:00pm Hall A Poster 3102 Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors. Villalona-Calero M Spigel D Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology